Orit Cohen‐Barak - Concepedia

Concepedia

Author

Orit Cohen‐Barak

Teva Pharmaceuticals (Israel)

Also Known As

O Cohen-Barak, O. Cohen-Barak, Orit Cohen-Barak, Orit Cohen‐Barak

24

Publications

1.2K

Citations

16

H-Index

47

Concepts

All Affiliations

Teva Pharmaceuticals (Israel)Teva Pharmaceuticals (United States)University of Arizona Simulations Plus (United States)University of Minnesota

OC

About

Orit Cohen‐Barak is an author at Teva Pharmaceuticals (Israel) specializing in medicine, genetics, and gene expression.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	753
2	Cell Biology	4	4	219
3	Natural Sciences	1	1	42
4	Marrow Transplantation	1	1	21
5	Molecular Biology	1	1	42

Orit Cohen‐Barak

×

20

Publications

1.2K

Citations

16

H-Index

	Year	Citations
Mutations in the Human Orthologue of the Mouse underwhite Gene (uw) Underlie a New Form of Oculocutaneous Albinism, OCA4 J.M. Newton, Orit Cohen‐Barak, Nobuko Hagiwara, The American Journal of Human Genetics Knockout MouseOculocutaneous AlbinismAllelic VariantDevelopmental BiologyGenetic Disorder	2001	355
Predicting Phenotype from Genotype: Normal Pigmentation* Robert K. Valenzuela, M. Henderson, Monica H. Walsh, Journal of Forensic Sciences	2010	134
Sox6 Directly Silences Epsilon Globin Expression in Definitive Erythropoiesis Zanhua Yi, Orit Cohen‐Barak, Nobuko Hagiwara, PLoS Genetics Sox6 RegulationTranscriptional RegulationDevelopmental BiologyBone Morphogenic ProteinHeme Homeostasis	2006	116
Sox6 regulation of cardiac myocyte development Orit Cohen‐Barak Nucleic Acids Research	2003	65
Safety, pharmacokinetics, and pharmacodynamics of TV‐1380, a novel mutated butyrylcholinesterase treatment for cocaine addiction, after single and multiple intramuscular injections in healthy subjects Orit Cohen‐Barak, Jacqueline Wildeman, Jeroen van de Wetering, The Journal of Clinical Pharmacology Healthy SubjectsPsychotropic MedicationPharmacotherapyButyrylcholinesterase TreatmentAddiction Medicine	2014	62
A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects Orit Cohen‐Barak, Sivan Weiss, Michèle Rasamoelisolo, Cephalalgia	2018	54
A 122.5-Kilobase Deletion of the P Gene Underlies the High Prevalence of Oculocutaneous Albinism Type 2 in the Navajo Population Zanhua Yi, Nanibaa’ A. Garrison, Orit Cohen‐Barak, The American Journal of Human Genetics Allelic VariantGenetic DisorderGeneticsGenetic EpidemiologyHematology	2003	53
Cloning, characterization and chromosome mapping of the human SOX6 gene Orit Cohen‐Barak, Nobuko Hagiwara, Martin F. Arlt, Gene Developmental BiologyCytogeneticsGeneticsChromosome BiologyMolecular Genetics	2001	51
Assessment of Pharmacokinetic and Pharmacodynamic Interactions Between Albumin-Fused Mutated Butyrylcholinesterase and Intravenously Administered Cocaine in Recreational Cocaine Users Megan J. Shram, Orit Cohen‐Barak, Bijan Chakraborty, Journal of Clinical Psychopharmacology	2015	50
Identification of a Novel Transcription Factor Binding Element Involved in the Regulation by Differentiation of the Human Telomerase (hTERT) Promoter Maty Tzukerman, Catherine M. Shachaf, Yael Ravel, Molecular Biology of the Cell GeneticsTelomerase ActivityMolecular BiologyGene Regulatory NetworkGene Transcription	2000	42

Page 1